Li, Rong-sheng published the artcileComparison on efficacy of different doses of butorphanol combined with preoperative parecoxib sodium for postoperative patient-controlled intravenous analgesia in female patients, COA of Formula: C19H17N2NaO4S, the publication is Guangdong Yixue (2015), 36(4), 605-607, database is CAplus.
Objective: To explore the appropriate dose of butorphanol combined with preoperative parecoxib sodium for postoperative patient-controlled i.v. analgesia. Methods: 75 Cases of ASA I-II female patients undergoing lower abdomen or lower limb operation were selected. All patients underwent operation under spinal-epidural combined anesthesia. After operation, the patients were given butorphanol 6 mg (group A, n = 25), 8 mg (group B, n = 25) and 10 mg (group C, n = 25), resp. for patient-controlled i.v. analgesia. The above-mentioned butorphanol was diluted as 100 mL with physiol. saline solution The amount of background infusion was 1.8 mL/h, and the single dose was 2 mL. The patients were i.m. injected with tramadol 100 mg for rescue analgesia. Before incision, all patients were given parecoxib sodium 40 mg. After operation, the pain visual analog score (VAS score) and Ramsay sedation score (RSS score) were observed The adverse reactions and satisfaction of patients were recorded. Results: 6, 12 and 24 h after operation, the VAS score in group B and group C was significantly lower than that in group A (P < 0.05, P < 0.01). 48 H after operation, the usage amount of butorphanol in group A, group B and group C was successively increased (P < 0.01). The incidence (24%) of dizziness in group C was higher than that (4%) in group A. The proportion (24%) of rescue analgesia in group A was higher than that (4%) in the other two groups (P < 0.05). The VAS score and RSS score in three groups had no statistically significant difference (P > 0.05). Conclusion: For the female patients undergoing lower abdomen or lower limb operation, preoperative i.v. injection of parecoxib sodium 40 mg combined with postoperative 1.8 mL/h butorphanol 8 mg is suitable for patient-controlled i.v. analgesia.
Guangdong Yixue published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C19H17N2NaO4S, COA of Formula: C19H17N2NaO4S.
Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem